Experic LLC eyes importing THC – public input deadline looms
Published Date: 8/26/2026
Notice
Summary
Experic LLC wants to become an official importer of some controlled substances, including certain drugs like tetrahydrocannabinols and nabilone. People and companies already registered can share their thoughts or ask for a hearing by September 25, 2026. This move could impact businesses dealing with these substances, so keep an eye on the deadline to have your say!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Application to Import Three Controlled Drugs
On July 17, 2026, Experic LLC applied to be registered to import three controlled substances: tetrahydrocannabinols (code 7370, Schedule I), 5‑Methoxy‑N‑N‑dimethyltryptamine (code 7431, Schedule I), and nabilone (code 7379, Schedule II). The company says the imports would be for internal research and clinical trial purposes only.
No Commercial Finished Dosage Imports Allowed
If approved, the registration will not allow Experic LLC to import Food and Drug Administration (FDA)-approved or non-approved finished dosage forms for commercial sale. Approval is limited to activities consistent with 21 U.S.C. 952(a)(2).
Sept 25, 2026 Comment and Hearing Deadline
Registered bulk manufacturers and applicants may submit electronic comments or objections, or file a written request for a hearing, on or before September 25, 2026 using https://www.regulations.gov or by mail to the Drug Enforcement Administration hearing addresses listed in the notice. Comments submitted through the portal will receive a Comment Tracking Number upon successful submission.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20748, Schedules of Controlled Substances: Placement of O-Desmethyltramadol in Schedule I; Correction
The DEA fixed a small mistake in their August 2026 rule that put O-desmethyltramadol and all its related forms into Schedule I, meaning it's now officially a highly controlled substance. This correction makes sure every version of the drug is covered, starting retroactively from August 12, 2026, through August 12, 2028. Anyone handling this drug should know it’s tightly regulated now, with no changes to fees but serious legal controls in place.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-17384, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Request for Comment; Consolidated Child Restraint System Registration for Defect Notifications and Labeling
In compliance with the Paperwork Reduction Act of 1995 (PRA), this notice announces that the Information Collection Request (ICR) summarized below will be submitted to the Office of Management and Budget (OMB) for review and approval. The ICR describes the nature of the information collection and its expected burden. This document request for comments on a reinstatement and revision of a previously- approved information collection on Child Restraint System Registration for Defect Notifications and Labeling. A Federal Register Notice with a 60-day comment period soliciting comments on the following information collection was published on December 5, 2023 (88 FR 84514). No comments were received.
Next: 2026-17386, Bulk Manufacturer of Controlled Substances Application: Chemtos, LLC
Chemtos, LLC wants to become a big-time maker of certain controlled substances, mostly strong drugs listed as Schedule I. This affects drug manufacturers and regulators who can comment or ask for a hearing by October 26, 2026. No direct costs are mentioned, but this move could impact drug supply and control efforts.